Pharmaceutical use

Abstract

The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and α-lipoic acid and/or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and α-lipoic acid and/or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.

1 - 20 . (canceled) 
     
     
         21 . A method for treating a subject diagnosed with a hormone-dependent disease, the method comprising treating the subject with a treatment effective amount of a pharmaceutical medication comprising as active ingredients an aromatase-inhibitor and an antioxidant that is different from the aromatase-inhibitor. 
     
     
         22 . The method according to  claim 21 , wherein the treatment is effective only in a peripheral, intracrine target tissue. 
     
     
         23 . The method according to  claim 21 , further comprising administering the pharmaceutical medication topically. 
     
     
         24 . The method according to  claim 21 , wherein the hormone-dependent disease is breast cancer. 
     
     
         25 . The method according to  claim 24 , wherein the method effects an adjuvant or a neoadjuvant therapy of breast cancer. 
     
     
         26 . The method according to  claim 24 , wherein the method effects a primary or a secondary prophylaxis of breast cancer. 
     
     
         27 . The method according to  claim 24 , further comprising administering the pharmaceutical medication topically. 
     
     
         28 . The method according to  claim 21 , wherein the hormone-dependent disease is prostate cancer or prostate hypertrophy. 
     
     
         29 . The method according to  claim 28 , further comprising administering the pharmaceutical medication topically. 
     
     
         30 . The method according to  claim 21 , wherein the hormone-dependent disease is mastopathy. 
     
     
         31 . The method according to  claim 30 , further comprising administering the pharmaceutical medication topically. 
     
     
         32 . The method according to  claim 21 , wherein the hormone-dependent disease is mastodynia or mastalgia. 
     
     
         33 . The method according to  claim 32 , further comprising administering the pharmaceutical medication topically. 
     
     
         34 . A method for treating a subject diagnosed with benign tumors, the method comprising treating the subject with a treatment effective amount of a pharmaceutical medication comprising as active ingredients an aromatase-inhibitor and an antioxidant that is different from the aromatase-inhibitor. 
     
     
         35 . The method according to  claim 34 , wherein the benign tumors are lipomatoses. 
     
     
         36 . The method according to  claim 35 , wherein the benign tumors are lipomatoses of the type of a Madelung's disease. 
     
     
         37 . The method according to  claim 34 , further comprising administering the pharmaceutical medication topically. 
     
     
         38 . The method according to  claim 21 , wherein the pharmaceutical medication further comprises one or more anti-androgenic active ingredients. 
     
     
         39 . The method according to  claim 38 , wherein one or more of the anti-androgenic active ingredients is a 5-alpha-reductase inhibitor or an androgen receptor blockers. 
     
     
         40 . The method according to  claim 21 , wherein the aromatase-inhibitor is a steroidal aromatase inactivator. 
     
     
         41 . The method according to  claim 40 , wherein the steroidal aromatase inactivator is selected from the group consisting of 4-hydroxyandrostenedione, exemestane, 4-acetoxyandrostenedione, 5-α-androst-3-ene-17-one and 3-α, 4-α-epoxy-5-α-androstane-17-one. 
     
     
         42 . The method according to  claim 21 , wherein the antioxidant is selected from the group consisting of flavonoids; vitamins; carotenoids; minerals; hormones; steroids; ubichinones; N-acetylcystein; α lipoic acid; extract of green tea containing polyphenols; glutathione; glutathionperoxidase; superoxide dismutase and catalase. 
     
     
         43 . A pharmaceutical medication for treating a subject diagnosed with a hormone-dependent disease, the medication comprising as active ingredients an aromatase-inhibitor and an antioxidant that is different from the aromatase-inhibitor. 
     
     
         44 . The pharmaceutical medication according to  claim 43 , wherein the antioxidant is an antioxidative effective composition of polyphenols, amino acids, mineral nutrients (trace elements) and polysaccharides. 
     
     
         45 . The pharmaceutical medication according to  claim 43 , further comprising as active ingredients 4-hydroxyandrostenedione and α-lipoic acid. 
     
     
         46 . The pharmaceutical medication according to  claim 43 , comprising as active ingredients exemestane and an extract of green tea containing polyphenols. 
     
     
         47 . The pharmaceutical medication according to  claim 43 , comprising as active ingredients exemestane and an antioxidative effective composition of polyphenols, amino acids, mineral nutrients (trace elements) and polysaccharides. 
     
     
         48 . A pharmaceutical composition, comprising:
 an aromatase-inhibitor, and   α-lipoic acid and/or a substance selected from the group consisting of antioxidative effective composition of polyphenols.   
     
     
         49 . The composition according to  claim 48 , wherein the antioxidative effective composition of polyphenols is a green tea extract containing polyphenols. 
     
     
         50 . The composition according to  claim 48 , further comprising hyaluronic acid as an additive. 
     
     
         51 . The composition according to  claim 48 , further comprising amino acids, mineral nutrients (trace elements) and polysaccharides as an additive. 
     
     
         52 . The composition according to  claim 48 , wherein the aromatase-inhibitor is selected from the group consisting of 4-hydroxyandrostenedione, exemestane, 4-acetoxyandrostenedione, 5-α-androst-3-ene-17-one.